RNA splicing is the process by which introns are removed 44 from mRNA precursors (pre-mRNAs) and is achieved by the 45 spliceosome, composed of five small nuclear RiboNucleoPro-46 tein complexes (U1, U2, U4, U5, and U6 snRNPs) and more 47 than 200 additional polypeptides. 6,7 Introns are recognized via 48 specific sequence signals located at their boundaries: a short 49 (6−8 nucleotides) consensus at the 5′ splice site (5′ss) and 
small RNA components (snRNAs) and the pre-mRNA. The activity of the compounds was tested in in vitro 183 biochemical assays of spliceosome (complex A) assembly and 184 in cell culture assays by assessing MCL1 alternative splicing 185 regulation and cytotoxicity. The structure of the drug variants t1 186 and their activities are summarized in Figure 1 and The synthesis of triene 1 was performed (Scheme 1) using Improved protocol of preparation of diene 16 developed by 228 Webb produces diasteromeric mixture E,E and E,Z with a ratio 229 of 9:1. In our hands, this mixture as well as TBS protected 230 alcohol could be separated by column chromatography, and a 231 pure sample of 17 was collected and converted into sudemycin 232 C1 diastereoisomer, compound 4 (Scheme 1).
233 When these derivatives were tested for activity, reduction to a 234 single double bond (in both E and Z diasteroisomer 235 configurations, 2 and 3, Figure 1 ) completely suppressed the 236 drug's activity, while the 1 triene displayed highly reduced but 237 still detectable activity in splicing assays but negligible in f2f3 238 cytotoxicity assays (Table 1, Figure 2G and H, Figure 3) . On 239 the other hand, the Z,E,Z diastereomer of sudemycin C1, 240 harboring opposite stereochemistry at the double bond (4, 241 Table 1 , Figures 1, 2A ,B, and 3) displays lower but still 242 significant activities (particularly in cytotoxic assays) despite the 243 dramatic change in spatial orientation of key pharmacophore 244 components (Table 1) . 245 Cyclohexane Substitution by Piperazine or 1,3-246 Dioxane. In previous studies, substitution of the cyclohexane 247 ring by a dioxane improved drug solubility. 46 With the aim of 248 further increasing aqueous solubility, three novel compounds 249 harboring piperazine rings were synthesized (5a, 5b, and 6, 250 Figure 1 ).
251
The formation of the sudemycin derivatives with a piperazine 252 s2 core (Scheme 2) started from commercially available tert-butyl These compounds showed very low activity in splicing or cell 275 proliferation tests and no detectable activity in in vitro assays, 276 revealing the requirement of the cyclohexane ring for 277 sudemycin's function (Table 1, Figures 2G,H and 3) . In 278 agreement with previous results, 47 substitution of sudemycin 279 D6 cyclohexyl group by a dioxane also reduced strongly the 280 drug's activity (sudemycin F2, 47 Figure 1 and Table 1 , Figure 3 , 281 Supporting Information Figure 1A and C). Figure 1 ). As amide groups are less susceptible to 290 hydrolysis than ester groups, these compounds might display 291 higher stability and efficacy.
292
Sudemycin K was obtained by reaction of the acid 27 with 293 the amine previously obtained in the reduction of azide 16 s3 294 (Scheme 3). The acid 27 was obtained from commercially 295 available L-alanine methyl ester hydrochloride by trans-296 formation into amide 24 followed by ester reduction to 297 aldehyde 25. Olefination of 25 to give Z-26 was achieved using 298 Still-Gennari protocol with good diastereoselectivity (dr = 299 92:8). The hydrolysis of ester Z-26 using conventional methods 300 (LiOH, NaOH) led to decomposition; however, using milder 301 reagents like trimethyltin hydroxide, the desired acid with 302 moderate yield was obtained. Acid 30 needed for the 303 preparation of carbamate 8 was obtained in a similar way 304 (Scheme 3) starting from commercial aldehyde 28. The main 305 advantage of this synthetic process lies in greater convergence 306 and fewer synthetic steps than previously described, with a 307 similar yield.
308
Replacing the oxycarbonyl by an amide group (sudemycin K, 309 Figure 1 ) resulted in a compound with higher activity than 310 sudemycin D6, the most potent sudemycin described so far, 311 both in biochemical spliceosome assembly assays as well as in 312 cellular assays for MCL1 alternative splicing and for cytotoxicity 313 (Table 1 , Figures 2C−F and 3) . The solubility of sudemycin K 314 and D6 was found to be comparable (Supporting Information). 315 Because the higher activity of sudemycin K was observed both 316 in short-term alternative splicing regulation of MCL1 and in 317 long-term increased cytotoxicity assays, the improved activity is 318 likely contributed both by direct effects on the splicing 319 machinery and by improved cell permeability or in vivo 320 stability. The replacement of the ester by an amide group could 321 make sudemycin K less sensitive to esterases, present for 322 example in plasma and microsomes 50 and believed to be the 323 main factor responsible for the observed short in vivo half-life of 324 sudemycin C1. 45 Indeed, we observed higher stability of this 325 compound upon incubation in culture medium containing fetal f4 326 bovine serum (Figure 4 ). Replacing the isopropyl by a 327 carbamate (8, Figure 1) we also found that both the compound harboring a triene Standard deviations are shown. Higher activity of sudemycin K than sudemycin D6 was significant (t test, p value < 0.01). (C) Cytotoxicity assays. Cell viability was measured using Resazurin assays 72 h after drug exposure. Graphs indicate the fraction of living cells compared to control DMSO treatment. All treatments were performed in triplicate, and standard deviations are shown. Drug treatments were clustered according to the different concentration ranges at which they induce significant decreases in cell viability. Higher activity of sudemycin K than sudemycin D6 was significant (t test, p value < 0.01). 384 carbonyl by an amide group makes it no longer a substrate of 385 esterases, believed to be the main factor responsible for the 386 short half-life of sudemycin C1 in vivo. Hsu, T. Y., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., 469 Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., Karlin, 470 K. L., Dominguez-Vidana, R., Hartman, J. D., Renwick, A., Scorsone, 471 K., Bernardi, R. J., Skinner, S. O., Jain, A., Orellana, M., Lagisetti, C., 472 Golding, I., Jung, S. Y., Neilson, J. R., Zhang, X. H., Cooper, T. A., 473 Webb, T. R., Neel, B. G., Shaw, C. A., and Westbrook, T. F. (2015) 474 The spliceosome is a therapeutic vulnerability in MYC-driven cancer. 475 Nature 525, 384−388.
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